<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01719367</url>
  </required_header>
  <id_info>
    <org_study_id>Kolek 01</org_study_id>
    <nct_id>NCT01719367</nct_id>
  </id_info>
  <brief_title>Genetically Determined Response to Atenolol in Patients With Persistent Atrial Fibrillation</brief_title>
  <official_title>Genetically Determined Response to Atenolol in Patients With Persistent Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atrial fibrillation (AF), the most common sustained heart rhythm disorder, is becoming
      increasingly prevalent in the Western world. The number of people with AF in the United
      States is projected to roughly double by the year 2050, to an estimated 6-12 million. For
      many patients with AF, rate control with atrioventricular (AV) node blockers is a widely
      accepted therapeutic strategy. These agents control heart rate, thus preventing symptoms and
      systolic heart failure associated with tachycardia due to a rapid ventricular response to AF.
      Beta-blockers are widely accepted as first line agents for rate control in AF, especially
      when patients have concomitant hypertension (HTN), coronary artery disease, cardiomyopathies,
      or heart failure (HF). As a class, beta-blockers are among the most commonly prescribed
      cardiovascular medications.

      Among patients with AF treated with beta-blockers, the heart rate (HR) response varies
      substantially. Sometimes, adequate rate control can be achieved by titration of the
      beta-blocker dose; but frequently, additional AV nodal blockers and/or digoxin are necessary.
      In some cases, adequate rate control cannot be achieved even with the simultaneous use of
      multiple AV nodal blockers, necessitating mechanical ablation of the AV node and permanent
      pacemaker implantation.

      Patient-specific variables that influence the response to beta-blockers include comorbid
      conditions, weight, age, and level of physical activity. Ethnic differences in the response
      to beta-blockers for the treatment of HTN and HF are well-described. However, the
      contribution of genetic variants to beta-blocker efficacy in AF is unknown. We propose to
      study, using a candidate gene approach, the effect of genetic variants on heart rate response
      to beta-blockade in patients with AF.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ventricular rate response during exercise.</measure>
    <time_frame>1 day</time_frame>
    <description>After baseline vital signs and ECG are recorded, patients will be asked to perform a baseline standardized (modified Bruce) exercise protocol. Heart rate will be recorded during each stage of the exercise protocol. Patients will be asked to exercise to sub-maximal exertion. After the baseline exercise protocol, patients will be given a single dose of oral atenolol. After a two hour waiting period to allow for peak effect of atenolol, patients will repeat the exercise protocol. The primary study outcome measure will be the difference in pre- and post-atenolol ventricular rate response to exercise. The primary outcome measure will be compared in patients with various polymorphisms in genes that might play a role in the inter-individual response to atenolol.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Atenolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will undergo a standardized, graded exercise protocol before ank after receiving a dose of oral atenolol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atenolol</intervention_name>
    <arm_group_label>Atenolol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must be at least 18 years of age.

          -  Subjects must have a history of persistent AF currently treated with a rate control
             strategy.

          -  Subjects should be willing to give written, informed consent.

          -  Subjects must be willing and able to participate in the exercise protocol.

        Exclusion Criteria:

          -  New York Heart Association Class III or IV heart failure.

          -  A history of heart failure induced by tachy-arrhythmia.

          -  A history of coronary artery disease and the presence of at least one of the
             following:

               -  Canadian Class III or IV angina.

               -  Recent myocardial infarction, coronary artery bypass grafting, or percutaneous
                  coronary intervention within 6 months.

          -  Severe renal or hepatic impairment.

          -  Subjects who have a clinically significant allergy/intolerance to atenolol, including
             a history of beta-blocker induced bronchospasm.

          -  Females who are pregnant or nursing.

          -  History of severe AV node dysfunction/pacemaker dependence.

          -  Subjects who have a systolic blood pressure &lt; 90 mm Hg or resting VR &lt;50 or &gt;120 per
             minute on the day of the study.

          -  Patients currently taking Vaughan-Williams Class I or III anti-arrhythmic drugs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>European Heart Rhythm Association; Heart Rhythm Society, Fuster V, Ryd√©n LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B, Priori SG, Blanc JJ, Budaj A, Camm AJ, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Zamorano JL; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines; Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol. 2006 Aug 15;48(4):854-906. Erratum in: J Am Coll Cardiol. 2007 Aug 7;50(6):562..</citation>
    <PMID>16904574</PMID>
  </reference>
  <reference>
    <citation>Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001 May 9;285(18):2370-5.</citation>
    <PMID>11343485</PMID>
  </reference>
  <reference>
    <citation>Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, Seward JB, Tsang TS. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006 Jul 11;114(2):119-25. Epub 2006 Jul 3. Erratum in: Circulation. 2006 Sep 12;114(11):e498.</citation>
    <PMID>16818816</PMID>
  </reference>
  <reference>
    <citation>Beta-Blocker Evaluation of Survival Trial Investigators, Eichhorn EJ, Domanski MJ, Krause-Steinrauf H, Bristow MR, Lavori PW. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001 May 31;344(22):1659-67.</citation>
    <PMID>11386264</PMID>
  </reference>
  <reference>
    <citation>Havlik RJ, Garrison RJ, Fabsitz R, Feinleib M. Variability of heart rate, P-R, QRS and Q-T durations in twins. J Electrocardiol. 1980;13(1):45-8.</citation>
    <PMID>7188949</PMID>
  </reference>
  <reference>
    <citation>Hanson B, Tuna N, Bouchard T, Heston L, Eckert E, Lykken D, Segal N, Rich S. Genetic factors in the electrocardiogram and heart rate of twins reared apart and together. Am J Cardiol. 1989 Mar 1;63(9):606-9.</citation>
    <PMID>2919564</PMID>
  </reference>
  <reference>
    <citation>Levin MC, Marullo S, Muntaner O, Andersson B, Magnusson Y. The myocardium-protective Gly-49 variant of the beta 1-adrenergic receptor exhibits constitutive activity and increased desensitization and down-regulation. J Biol Chem. 2002 Aug 23;277(34):30429-35. Epub 2002 May 28.</citation>
    <PMID>12034720</PMID>
  </reference>
  <reference>
    <citation>Mason DA, Moore JD, Green SA, Liggett SB. A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor. J Biol Chem. 1999 Apr 30;274(18):12670-4.</citation>
    <PMID>10212248</PMID>
  </reference>
  <reference>
    <citation>Sandilands A, Yeo G, Brown MJ, O'Shaughnessy KM. Functional responses of human beta1 adrenoceptors with defined haplotypes for the common 389R&gt;G and 49S&gt;G polymorphisms. Pharmacogenetics. 2004 Jun;14(6):343-9.</citation>
    <PMID>15247626</PMID>
  </reference>
  <reference>
    <citation>Mialet Perez J, Rathz DA, Petrashevskaya NN, Hahn HS, Wagoner LE, Schwartz A, Dorn GW, Liggett SB. Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat Med. 2003 Oct;9(10):1300-5. Epub 2003 Sep 14.</citation>
    <PMID>14502278</PMID>
  </reference>
  <reference>
    <citation>Liu J, Liu ZQ, Yu BN, Xu FH, Mo W, Zhou G, Liu YZ, Li Q, Zhou HH. beta1-Adrenergic receptor polymorphisms influence the response to metoprolol monotherapy in patients with essential hypertension. Clin Pharmacol Ther. 2006 Jul;80(1):23-32. Epub 2006 Jun 8.</citation>
    <PMID>16815314</PMID>
  </reference>
  <reference>
    <citation>Johnson JA, Zineh I, Puckett BJ, McGorray SP, Yarandi HN, Pauly DF. Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin Pharmacol Ther. 2003 Jul;74(1):44-52.</citation>
    <PMID>12844134</PMID>
  </reference>
  <reference>
    <citation>Small KM, Forbes SL, Rahman FF, Bridges KM, Liggett SB. A four amino acid deletion polymorphism in the third intracellular loop of the human alpha 2C-adrenergic receptor confers impaired coupling to multiple effectors. J Biol Chem. 2000 Jul 28;275(30):23059-64.</citation>
    <PMID>10801795</PMID>
  </reference>
  <reference>
    <citation>Lobmeyer MT, Gong Y, Terra SG, Beitelshees AL, Langaee TY, Pauly DF, Schofield RS, Hamilton KK, Herbert Patterson J, Adams KF Jr, Hill JA, Aranda JM Jr, Johnson JA. Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure. Pharmacogenet Genomics. 2007 Apr;17(4):277-82.</citation>
    <PMID>17496726</PMID>
  </reference>
  <reference>
    <citation>K√§√§b S, Darbar D, van Noord C, Dupuis J, Pfeufer A, Newton-Cheh C, Schnabel R, Makino S, Sinner MF, Kannankeril PJ, Beckmann BM, Choudry S, Donahue BS, Heeringa J, Perz S, Lunetta KL, Larson MG, Levy D, MacRae CA, Ruskin JN, Wacker A, Sch√∂mig A, Wichmann HE, Steinbeck G, Meitinger T, Uitterlinden AG, Witteman JC, Roden DM, Benjamin EJ, Ellinor PT. Large scale replication and meta-analysis of variants on chromosome 4q25 associated with atrial fibrillation. Eur Heart J. 2009 Apr;30(7):813-9. doi: 10.1093/eurheartj/ehn578. Epub 2009 Jan 13.</citation>
    <PMID>19141561</PMID>
  </reference>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 29, 2012</study_first_submitted>
  <study_first_submitted_qc>October 31, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2012</study_first_posted>
  <last_update_submitted>October 31, 2016</last_update_submitted>
  <last_update_submitted_qc>October 31, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Matt Kolek</investigator_full_name>
    <investigator_title>Fellow in Cardiovascular Disease</investigator_title>
  </responsible_party>
  <keyword>Baseline (pre-atenolol)</keyword>
  <keyword>Post-atenolol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atenolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

